Trial Profile
A Phase 1b Study of Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastatic Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVETAX
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 01 Sep 2021 Planned End Date changed from 28 Feb 2021 to 23 Feb 2026.
- 01 Sep 2021 Planned primary completion date changed from 28 Feb 2021 to 23 Feb 2026.